Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

NCT ID: NCT07792681
Registry status: Not yet recruiting
Study type: Interventional
Phase: Phase 2 / Phase 3
Sponsor: Brise Pharmaceuticals Co., Ltd.
Conditions: Migraine, With or Without Aura

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study Evaluating the Efficacy and Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

Enrollment: 2079 participants (Estimated).

What is being studied

Drug: BR005-036C
Drug: Placebo

Who may be eligible

Ages: 18 Years to no maximum
Sex: All
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: 1. Male or female Participants aged 18 years or older. 2. Patients diagnosed with migraine with or without aura in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3), with a disease history of at least 1 year. 3. Onset age of migraine shall be less than 50 years old. 4. At least 2-8 moderate-to-severe migraine attacks per month within 3 months prior to screening visit. 5. Fewer than 15 headache days (migraine or non-migraine) per month within 3 months prior to screening visit. 6. Patients on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to study entry. Exclusion Criteria: 1. Patient with a history of or diagnosed with brainstem aura migraine, hemiplegic migraine, retinal migraine, new-daily-persistent headache, trigeminal autonomic cephalalgias or cranial neuralgia. 2. Patient with clinically significant cardiovascular, cerebrovascular, hematological, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurological or psychiatric disorders; patient with other confounding acute or chronic pain syndromes, dementia, epilepsy, or other diseases (other than migraine) that may interfere with study assessments. 3. Patient with a history of acute hepatitis within 6 months prior to screening, or any chronic liver diseases including non-alcoholic fatty liver disease, chronic viral hepatitis, liver cirrhosis. 4. Patient with a history of hematological or solid malignant neoplasms within 5 years prior to screening. 5. Abnormal electrocardiogram findings at screening: QTcF \>450 msec for male subjects; QTcF \>470 msec for female subjects. 6. Patient with uncontrolled hypertension. 7. History of alcohol or substance abuse within 6 months prior to screening. 8. Clinically significant laboratory abnormalities at screening: ALT, AST or total bilirubin \>1.5 × upper limit of normal (ULN); estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m². 9. Use of CGRP receptor antagonists within 1 month prior to screening or randomization; use of anti-CGRP or anti-CGRP-receptor monoclonal antibodies within 6 months prior to screening or randomization. 10. Use of acute migraine treatment medications for more than 10 days per month in 3 months prior to randomization (refer to Concomitant Medications section).

Study locations

83 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: China

Baoji, China: 1
Baotou, China: 1
Beijing Municipality, China: 6
Bengbu, China: 1
Cangzhou, China: 1
Changchun, China: 1
Changde, China: 1
Changsha, China: 5
Chongqing Municipality, China: 4
Dalian, China: 1
Dazhou, China: 1
Guangdong, China: 1
Guangzhou, China: 2
Hangzhou, China: 2
Harbin, China: 1
Hefei, China: 2
Hohhot, China: 1
Huanggang, China: 1
Huzhou, China: 1
Jinan, China: 3
Jingzhou, China: 1
Jining, China: 1
Kunming, China: 2
Lanzhou, China: 2
Lianyungang, China: 1
Liaocheng, China: 1
Luoyang, China: 1
Nanjing, China: 3
Nanyang, China: 1
Qingdao, China: 1

Sample of listed locations

Baoji Central Hospital — Shanxi, Baoji, 721008, China — Site recruitment status not specified in the registry data
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology — Inner Mongolia, Baotou, 014010, China — Site recruitment status not specified in the registry data
Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing Municipality, 100050, China — Site recruitment status not specified in the registry data
First Medical Center of Chinese PLA General Hospital — Beijing, Beijing Municipality, 100853, China — Site recruitment status not specified in the registry data
Peking Union Medical College Hospital — Beijing, Beijing Municipality, 100005, China — Site recruitment status not specified in the registry data
Peking University People's Hospital — Beijing, Beijing Municipality, 100044, China — Site recruitment status not specified in the registry data
Peking University Third Hospital — Beijing, Beijing Municipality, 100191, China — Site recruitment status not specified in the registry data
Xuanwu Hospital, Capital Medical University — Beijing, Beijing Municipality, 100053, China — Site recruitment status not specified in the registry data
The First Affiliated Hospital of Bengbu Medical College — Anhui, Bengbu, 233004, China — Site recruitment status not specified in the registry data
Cangzhou Central Hospital — Hebei, Cangzhou, 061001, China — Site recruitment status not specified in the registry data
The Second Hospital of Jilin University — Jilin City, Changchun, 130022, China — Site recruitment status not specified in the registry data
Changde First People's Hospital — Hunan, Changde, 415000, China — Site recruitment status not specified in the registry data
Changsha Central Hospital — Hunan, Changsha, 410004, China — Site recruitment status not specified in the registry data
The Second Xiangya Hospital of Central South University — Hunan, Changsha, 410011, China — Site recruitment status not specified in the registry data
The Third Hospital of Changsha — Hunan, Changsha, 410000, China — Site recruitment status not specified in the registry data
The Third Xiangya Hospital of Central South University — Hunan, Changsha, 410013, China — Site recruitment status not specified in the registry data
Xiangya Hospital of Central South University — Hunan, Changsha, 410008, China — Site recruitment status not specified in the registry data
Chonggang General Hospital — Chongqing, Chongqing Municipality, 400084, China — Site recruitment status not specified in the registry data
Chongqing University Three Gorges Hospital — Chongqing, Chongqing Municipality, 404000, China — Site recruitment status not specified in the registry data
The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, 400016, China — Site recruitment status not specified in the registry data
The Fourth People's Hospital of Chongqing (Chongqing Emergency Medical Center) — Chongqing, Chongqing Municipality, 400014, China — Site recruitment status not specified in the registry data
Dalian Municipal Central Hospital, Affiliated to Dalian University of Technology — Liaoning, Dalian, 116033, China — Site recruitment status not specified in the registry data
Dazhou Central Hospital — Sichuan, Dazhou, 635000, China — Site recruitment status not specified in the registry data
Guangdong Provincial People's Hospital — Guangzhou, Guangdong, 510080, China — Site recruitment status not specified in the registry data
Guangzhou First People's Hospital — Guangdong, Guangzhou, 510180, China — Site recruitment status not specified in the registry data

Study details

Start date: September 15, 2026
Primary completion date: June 30, 2028
Completion date: July 31, 2028
First posted: August 28, 2026

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07792681
Registry last updated: September 16, 2026
QualifiedStudies registry data refreshed: October 5, 2026
QualifiedStudies record fetched: October 5, 2026

View NCT07792681 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Migraines studies | Clinical trial FAQ